Blood Cancer Talks

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:  1.      STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL https://library.ehaweb.org/eha/2024/eha2024-congress/413651...

In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed: 1.      Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL0 2.     EVIDEN...

In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic.  The key studies and trials discussed are as follows:   ·        GIPSS : Genetically inspired prognostic scoring system that is exclusively based on genetic markers.   §  https://www.nature.com/articles/s41375-018-0107-z   ·        MIPSS70+ Version 2.0 : Mutation and Karyotype-Enhanced Intern...

In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation):  https://pubmed.ncbi.nlm.nih.gov/28742454/   2. Myeloma XI RCT (lenalidomide vs observation): htt...

In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1.       IPSET (revised) system , risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: ·        Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated ·        Low risk: No prior thrombosis, age ≤60 years, JAK2...

In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center.  RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/ FDA...

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic. 

In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic.  Here are the key articles discussed: 1.      Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/   2.     Mayo 2004 staging:  https://pubmed.ncbi.nlm.nih.gov/15365071/   3.     Mayo 2012 staging: https://www.ncbi.nlm.nih.gov/pmc/articl...

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel.  Here are the abstracts that were discussed: 1. TRANSFORM-1 : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelof...

In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota.  Here are the key trials we discussed: 1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and...

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode:  First, we will focus on a few abstracts in precursor states, MGUS.  1.      New diagnostic criteria for light chain MGUS (IStopMM):                https://ash.confex.com/ash/2023/webprogram/Paper188547.html              htt...

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.   Here are the abstracts that were discussed:   Mantle Cell Lymphoma   1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Muta...

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed:  1. Glofitamab for Relapsed/Refractory DLBCL: https://pubmed.ncbi.nlm.nih.gov/36507690/   2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL: https://pubmed.ncbi.nlm...

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl. Here are the shownotes: 1. Assessment of minimal residual disease in standard-risk AML  https://www.nejm.org/doi/full/10.1056/nejmoa1507471   2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation https://www.nejm.org/doi/full/10.1056/nejmoa1614359   3. QuANT...

In this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza.  We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair.  Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/dp/1541699521

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.  Here are the shownotes: 1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:  https://x.com/Rfonsi1/status/1206004966294294528?s=20   2. Natu...

In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes:  1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1     2. Elizabeth Schorb ASH 2022 (MARTA) 65-80 year olds –...

In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies.  Here are the key studies that we touched upon: 1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL: https://pubmed.ncbi.nlm.nih.gov/37315268/   2. Meta-analysis of >2500 patients with chromosome 1q21 abn...

In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed:  1. “ How I Treat Peripheral T-cell Lymphoma? ”: https://pubmed.ncbi.nlm.nih.gov/24615779/ 2...

In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes: 1. CCUS and risk of transformation to myeloid neoplasms: https://www.sciencedirect.com/science/article/pii/S0006497121013...

In this episode, we delve into the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria (PNH) with Dr. Robert Brodsky.  Here are the shownotes for key papers we discussed in the episode: How I treat PNH : https://pubmed.ncbi.nlm.nih.gov/33512400/ Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia : https://pubmed.ncbi.nlm.ni...

In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University. Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS Here are the key trials we discussed: 1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma): https://pubmed.ncbi.nlm....

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center. Here are some of the key articles we discussed: 1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.        https://pubmed.ncbi.nlm.nih.gov/36989488/   2. CAR-HEMATOTOX score:      https://pubmed.ncbi.nlm.nih.gov/341665...

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes: 1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9 2. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3...

In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed: 1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/ 2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619 3.  Talquetamab (MonumenTAL-1 trial): https://pubmed.nc...